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Abstract
Background:  CMV is a major clinical problem in transplant recipients. Thus, it is important to
use sensitive and specific diagnostic techniques to rapidly and accurately detect CMV infection and
identify patients at risk of developing CMV disease. In the present study, CMV infection after liver
transplantation was monitored retrospectively by two molecular biology assays - a quantitative
PCR assay and a qualitative NASBA assay. The results were compared with those obtained by
prospective pp65 antigenemia determinations.
Materials and Methods:  87 consecutive samples from 10 liver transplanted patients were tested
for CMV by pp65 antigenemia, and CMV monitor and NASBA pp67 mRNA assay.
Results:  CMV infection was detected in all patients by antigenemia and CMV monitor, whereas
NASBA assay identified only 8/10 patients with viremia. Furthermore, CMV infection was never
detected earlier by molecular biology assays than by antigenemia. Only 5/10 patients with CMV
infection developed CMV disease. Using a cut off value of 8 cells/50,000, antigenemia was found to
be the assay that better identified patients at risk of developing CMV disease. However, the kinetics
of the onset of infection detected by NASBA and CMV monitor seemed to have better identified
patients at risk of developing CMV disease. Furthermore, before onset of disease, CMV pp67
m R N A  wa s  f o u n d  t o  h a v e  s i m i l a r  o r  b e t t e r  n e g a t i v e  a n d  p o s i t i v e  p r e d i c t i v e  v a l u e s  f o r  t h e
development of CMV disease.
Conclusions:  The present data, suggests that the concomitant use of antigenemia and pp67
mRNA assay gives the best identification of patients at risk of developing CMV disease.
Background
Cytomegalovirus (CMV), a member of the human her-
pesvirus family, causes a lifelong persistent infection
that is usually well controlled by the host immune sys-
tem. However, in patients with defective immunity, as
recipients of allogeneic solid organ (SOT), bone marrow
transplants (BMT) and individuals infected with HIV,
CMV remains a major clinical problem [1,2]. For this rea-
son, diagnostic methods that rapidly and unequivocally
identify emerging CMV biologic activity (i.e. replication,
viral gene expression), preferably discriminating be-
tween subclinical and symptomatic infection are re-
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quired for optimal surveillance and management of CMV
infections.
CMV dissemination in the blood occurs during active in-
fection and viremia has been recognized as the major vi-
rological risk factor for the progression to clinical disease
[3]. In this respect, there have been numerous studies
that investigate the correlation of systemic CMV viral
load with symptomatic CMV disease in immunocompro-
mised patients [4,5,6,7,8,9,10,11,12,13,14]. Quantifica-
tion of the polymorphonuclear leucocytes expressing the
CMV tegument pp65 protein by the antigenemia assay,
can be used to predict CMV disease and to monitor anti-
viral treatment [4,5,6,7]. Equally, quantification of CMV
DNA load by PCR has been used as a marker for the pre-
diction of CMV disease [8,9,10,11,12,13,14]. The detec-
tion of mRNA for the viral matrix tegument pp67 protein
in blood leukocytes reflects viral transcriptional activity
and has also been showed to be a specific assay for mon-
itoring the onset of symptomatic CMV infection and an-
tiviral therapy [15,16,17].
In the present study we evaluated 3 methods for the di-
agnosis of CMV infection and the identification of pa-
tients at risk of developing CMV disease, before the onset
of disease. Quantitative pp65 antigenemia prospective
results were compared to the retrospectively obtained
data by quantitative PCR (CMV Monitor) and a qualita-
tive pp67 mRNA assay (Nuclisens CMV pp67) in a series
of consecutive samples from 10 liver transplant recipi-
ents, who had not received prophylactic treatment for
CMV infection.
Materials and Methods
Patients
Ten patients from the liver transplant program of the
Santo António General Hospital were included in the
study. These 10 patients were chosen out of a cohort of
34 patients. Selection criteria were that all patients had
one positive antigenemia determination and half of them
had clinical signs of CMV disease. Seven of the patients
were males and 3 were females. Patients' ages ranged
from 29 to 58 years, with an average of 38.5 years. One
patient was transplanted due to the presence of alcoholic
cirrhosis and 9 due to Familial Amiloidotic Polyneurop-
athy (FAP). Of these 8 had the Met 30 mutation, and 1
the Pro52 mutation. The immunosupression protocol in-
cluded 500 mg metilprednisolone at the beginning of the
surgery and at the anehepathic phase, followed by 4 dos-
es of 50 mg on the first day post-transplant, 4 doses of 40
mg on the second day, 4 doses of 30 mg on the third day,
4 doses of 20 mg on the 4th day, 2 doses of 20 mg on the
5th day, and one dose of 20 mg on the 6th day. Thereafter
a dose of 20 mg/day was administered until the end of
the 3rd month, 15 mg/day until the end of the first year,
10 mg/day until the end of the 18th month, 5 mg/day un-
til the end of the 2nd year, after which immunosupres-
sion was discontinued. The protocol also included the
administration of 50 mg azatioprin during the anhepath-
ic phase followed by 50 mg every 12 h during 30 days.
Neoral Ciclosporin was also administered, and the drug
level monitored by the Tdx method. Drug levels were
kept at 350-450 ng/ml during the 1st month post-trans-
plant, 250-350 ng/ml during the second and third
months, 150-250 ng/ml until the end of the first year,
and 75-150 ng/ml thereafter. Acute cellular rejection was
treated with 1 g metilprednisolone for 3 days and there-
after the reduction scheme followed on the post-trans-
plant was applied.
All patients were monitored for the presence of an active
infection of CMV, starting between the 1st and 2nd week
post-transplant, weekly during the first month and later
at each clinical appointment (one and 3 weeks after dis-
closure and monthly thereafter), or whenever it was clin-
ically relevant. A total of 87 samples were collected from
all 10 patients with an average of 8.7 samples per patient
(range of 4 to 12 samples). Twin blood samples were col-
lected on sterilized EDTA tubes. One of the samples was
prospectively tested by pp65 antigenemia and the result
was used for clinical management. The other sample was
retrospectively studied by molecular biology methods.
Scarcity of the available sample did not allow CMV pp67
determination on 5 specimens.
Two of the 10 patients were retransplanted. One of these
was retransplanted 24 h after the first transplant due to
the presence of a liver arterial thrombosis. The other pa-
tient, presented multiple liver abscesses, was retrans-
planted twice (3 and 7 weeks after the first transplant)
and died during the second retransplantation for reasons
not related to CMV infection.
Nine of the 10 patients were transfused with leucodeplet-
ed red blood cells.
Nine of the patients were CMV positive before trans-
plant, and the remainder patient was CMV negative.
All liver donors were CMV Ig positive.
CMV infection definition
CMV infection is defined as isolation and/or detection of
virus from any tissue or body fluid or serological conver-
sion to CMV in a patient who was seronegative before
transplantation. In the context of the present work, we
used antigenemia as the golden standard method for
CMV detection, and consequently CMV infection defini-
tion.BMC Infectious Diseases (2001) 1:2 http://www.biomedcentral.com/1471-2334/1/2
CMV disease definition
CMV disease is usually defined as CMV infection accom-
panied by clinical manifestations. The most common of
these is a viral syndrome with malaise, fever, leucopenia,
atypical lymphocytosis, thrombocitopenia, mild to mod-
erate elevations of serum aminotransferases often in a
self-limiting process that does not require treatment. Of
greater concern is organ involvement that may be local-
ized to a single organ or disseminated if there is involve-
ment of 2 or more non-contiguous organ sites. Organ
involvement is defined as histopathologic evidence of
CMV with or without a positive viral culture of involved
tissue.
In the context of the present work, CMV disease was de-
fined as presence of the above mentioned clinical signs in
association with positive pp65 antigenemia. Whenever
this happened, ganciclovir therapy (5 mg/Kg every 12
hours) was always initiated for 14 days, or until negative
antigenemia results were observed. Thus we considered
all patients who were not treated as without CMV dis-
ease. For the same reason, the moment of ganciclovir
prescription was considered as the onset of CMV disease.
Antigenemia pp65
CMV antigenemia assay was carried out on 3 ml of
EDTA-anticoagulated blood within 4 hours of specimen
collection. The pp65 antigen was detected with the com-
mercial assay CMV-vueTM (DiaSorin, Stillwater, Minne-
sota 55082-0285, USA), with a few modifications. The
antigenemia assay consists of four major steps - isolation
of the polymorphonuclear leukocytes from 3 mL of
EDTA-anticoagulated blood by dextran separation and
ressuspension of the leukocyte in PBS to give a final cell
density equivalent to 2 ×  106 leukocytes/mL; preparation
of two cytospin slides and fixation of the cells in formal-
dehyde; incubation with a mix of two mouse monoclonal
antibodies (C10 and C11) directed against the pp65 fol-
lowed by incubation with horseradish peroxidase-cou-
pled rabbit anti-mouse IgG after which a peroxidase
mediated chromogenic reaction takes place; quantifica-
tion under a light microscope by counting the number of
positively stained leukocytes and the total number of leu-
kocytes per slide. The results were given as the total
number of positive leukocytes/50.000 leukocytes.
Cobas amplicor CMV monitor
For quantification of CMV DNA, the commercial assay
Cobas Amplicor CMV Monitor Test (Roche Diagnostics
Systems, Inc., Branchburg, NJ, USA), directed against
the CMV polymerase gene, was performed on 200 µ l of
plasma according to the manufacturer recommenda-
tions (see ref. 12 for details). The results were expressed
as DNA copies per mL of plasma. The linear range of the
assay is 400-400.000 copies of CMV DNA per mL.
Nuclisens CMVpp67
Amplification and detection of CMV pp67 mRNA tran-
scripts was done on 100 µ l EDTA anti-coagulated blood
using the commercial assay Nuclisens pp67 Assay (Orga-
non Teknika, Boxtel, Netherlands) according to the man-
ufacturer's instructions (see 16 for details).
Total nucleic acids were isolated by the Boom guanidin-
ium thiocyanate-silica procedure in a semi-automated
procedure [18] with Nuclisens Automated Isolation Rea-
gents (Organon Teknika, Boxtel, Netherlands) and Nu-
clisens® Extractor (Organon Teknika).
The results were expressed as presence or absence of
CMV pp67 mRNA.
Statistical analysis
The performance of the 3 methods used, relative to the
prediction of the development of disease, was statistical-
ly analysed using the following definitions: Sensitivity
was calculated as the proportion of the determinations
done during disease episodes that tested positive; Specif-
icity was defined as the proportion of the determinations
done during disease-free episodes that tested negative;
Positive predictive value was calculated as the propor-
tion of "test-positive" determinations that occurred on
patients that developed disease; Negative predictive val-
ue was defined as the proportion of "test-negative" deter-
minations that occurred on patients that did not develop
disease.
Determinations on patients that developed disease were
compared with the results observed on assymptomatic
patients using the Mann-Whitney U test.
Results
Overall test performance
All 87 sequential specimens obtained from 10 liver trans-
plant recipients were assessed by CMV antigenemia and
CMV monitor, whereas only 82 specimens were available
for CMV pp67 mRNA assessment. The presence of an in-
ternal control in CMV monitor assay allowed the identi-
fication of 1/87 samples with amplification inhibitors. A
similar control was also present in the Nuclisens CMV
pp67 assay, revealing that none of the samples studied
showed signs of reaction inhibition. The results obtained
with the 3 tests were concordant in 58/82 samples
(70%). Of these, 57% (33/58) were negative and 43%
(25/58) were positive for CMV.
Taking the antigenemia determination as the "golden
standard" (the routine method used for clinical manage-
ment), all patients developed CMV infection. According
to the serostatus before transplantation, 1 patient had a
primary CMV infection. CMV monitor test detected CMVBMC Infectious Diseases (2001) 1:2 http://www.biomedcentral.com/1471-2334/1/2
infection in 10/10 patients, while CMV pp67 mRNA was
only capable of detecting the infection in 8/10 patients.
It must however be noted that the two discordant pa-
tients never developed CMV disease.
The onset of CMV infection was on average 31 days
(range 17-69) by antigenemia pp65, 40 days (range 23-
70) by CMV monitor, and 37 days (range 17-69) by pp67
mRNA assay. Contrary to our expectations, CMV positiv-
ity was never detected earlier by molecular biology as-
says than by antigenemia. In fact, the 4 patients with
discordant ascending kinetics (patients A, B, D and E -
Fig 1) presented a positive antigenemia result one deter-
mination earlier than the two other assays. It must how-
ever be noticed that: 1) two of the 4 patients had no CMV
pp67 determination at the discordant points; 2) antigen-
emia determination was in all cases only 1 positive cell/
50,000 cells, and; 3) none of the 4 patients ever devel-
oped CMV disease.
CMV pp67 mRNA assay was found to show positivity lat-
ter than CMV monitor, since 3 patients (A, D and E - Fig
1) had positive antigenemia, positive CMV monitor and
negative pp67 mRNA. Again it must be noted that none
of these patients ever developed CMV disease and CMV
pp67 mRNA assay was always negative for patients D
and E (fig 1). Considering CMV clearance as one negative
result by at least one CMV viremia assay, after being pos-
itive by the same assay, 8 patients (all but patients D and
F - fig 1 and 2) showed analytical signs of CMV clearance.
In these patients, antigenemia was found to be the first
test to become negative in 3/8 patients (H, I, J-fig 2).
Figure 1
Kinetics of CMV determination by antigenemia (squares), CMV monitor (small dots), and CMV pp67 mRNA
(circles), in the 5 patients that did not develop CMV disease. The right Y-axis was used for qualitative pp67 mRNA
assay: P = positive; N = negative.BMC Infectious Diseases (2001) 1:2 http://www.biomedcentral.com/1471-2334/1/2
Furthermore, this method was found to become negative
concomitantly to Nuclisens CMV in 3/8 patients (B, C
and I - Fig 1 and 2), whereas CMV monitor was the last
test to show CMV clearance in 4/8 patients (B, C, H, I-fig
1 and 2).
Correlation of analytical results to CMV disease
Only 5/10 patients developed clinical CMV disease, as
defined in the Materials and Methods section. On aver-
age, the onset of CMV disease was 36 days post-trans-
plant (range 30-43 days), and at this time all tests
showed positive results (fig 2).
Next, we compared the results of patients with and with-
out CMV disease. As can be seen on table 1, the onset of
CMV infection was detected roughly at the same time
(28-29 days) in patients with CMV disease by all 3 as-
says. In contrast, patients that did not develop CMV dis-
ease showed antigenemia pp65 positivity on average 16
days earlier than the 2 other molecular biology assays. As
a result, only molecular biology assays were found to dis-
tinguish the onset of infection between patients with and
without CMV disease clearly and in a statistically signifi-
cant way (table 1). Furthermore, it may be significant to
observe that the only test that remained negative in 2/5
patients without CMV disease was the pp67 mRNA as-
say. Also, quantitative results at the onset of infection
Figure 2
Kinetics of CMV determination by antigenemia (squares), CMV monitor (small dots), and CMV pp67 mRNA
(circles), in the 5 patients that developed CMV disease. The arrows indicate the onset of CMV disease, and the red
rectangles the period of ganciclovir administration. A black R on a red circle indicates a retransplantation surgery. Patient F
died at the second retransplantation surgery for reasons not related to CMV disease. The right Y axis was used for qualitative
pp67 mRNA assay: P = positive; N = negative.BMC Infectious Diseases (2001) 1:2 http://www.biomedcentral.com/1471-2334/1/2
were, on average, higher in patients with CMV disease as
compared to patients without CMV disease (table 2), al-
though the difference did not reach statistical signifi-
cance.
In order to identify the most sensitive method for the
identification of patients at risk of developing CMV dis-
ease, we compared results obtained on the available
samples before the onset of disease (one week on aver-
age; range 4-15 days). As can be seen on table 3, the re-
sults showed that if we set an antigenemia cut of value of
8/50,000 cells, patients with disease had antigenemia
results higher than the observed for patients without dis-
ease. The only exception among patients with disease
was patient J, that showed negative determinations 15
days before the onset of clinical disease, and no latter de-
termination was available before disease was observed.
Also, patient C, despite not developing CMV disease
showed one determination with 31 cells/50,000. Curi-
ously, at this stage, all methods showed positive values.
Table 1: Comparison of onset of CMV infection between patients with and without CMV disease
ONSET OF CMV INFECTION (days)
WITHOUT WITH CMV
CMV DISEASE DISEASE
Mean Min-max Mean Min-max p a)
Antigenemia pp65 b) 35 20-69 28 17-35 n.s.
CMV monitor c) 51 32-70 29 23-35 <0.029
CMV pp67 mRNA 51d) 37-69d) 28 17-35 <0.026
a) p = significance level for the difference between patients with and without disease, according to the Mann-Whitney U test; n .s.= not significant b) 
Antigenemia results are given as positive cells per 50,000 cells c) CMV monitor results are given as copies/mL d) Two patients  without CMV disease 
were always negative by CMV pp67 mRNA. Thus onset of CMV infection by this assay only includes data for 3/5 patients without CM V disease.
Table 2: Comparison of CMV load at the onset of infection between patients with and without CMV disease
PATIENTS WITHOUT PATIENTS WITH
CMV DISEASE CMV DISEASE
Mean Min-max Mean Min-max p a)
Antigenemia pp65 b) 7 1-31 17 1-40 n.s.
CMV monitor c) 4.2 ×  103 4.3 ×  102 - 1.6 ×  104 7.2 ×  103 9.4 ×  102 - 1.8 ×  104 n.s.
a) p = significance level for the difference between patients with and without disease, according to the Mann-Whitney U test; n .s. = not significant b) 
antigenemia results are given as positive cells per 50,000 cells c) CMV monitor results are given as copies/mLBMC Infectious Diseases (2001) 1:2 http://www.biomedcentral.com/1471-2334/1/2
Similarly, CMV monitor determinations were in general
above 2000 copies/mL in patients with disease, which is
in accordance with the literature [10,13]. Again, this cut-
off would include 2 patients that never developed disease
Table 3: Analytical results observed before onset of disease
Patient Patient pp65 CMV pp67 Days before onset
Group Antigenemia a,b monitor b,c mRNA of disease
F 27 18.3 ×  103 Positive 7
With G2 3 2 . 2 9   ×  103 Positive 9
CMV H 13 11.8 ×  103 Positive 9
                  Disease d) I 9 2.55 ×  103 Positive 4
J 0 Negative Negative 15
A 5 2.70 ×  103 positive -
Without B 5 1.18 ×  103 positive -
CMV C 31 16.0 ×  103 positive -
                  Disease e) D 1 1.54 ×  103 Negative -
E 2 0.43 ×  103 Negative -
a) Positive cells per 50,000 cells b) Differences observed between patients with and without disease, were not found to be statistically significant 
based on the Man-Whitney U test c) Copies/mL d)Values before onset of disease e) Maximum values observed
Table 4: Statistical comparison on the performance of the 3 methods used
specificity Sensitivity a) PPV NPV
Antigenemia pp65 67% 80% 63% 49%
globally CMV Monitor 63% 90% 69% 57%
Without pp67 mRNA b) 76% 85% 88% 58%
cut-off Antigenemia pp65 62% - 30% 73%
Before
CMV Monitor 64% - 28% 74%
treatment
pp67 mRNA b) 79% - 60% 76%
Antigenemia pp65 93% 65% 94% 54%
globally CMV Monitor 86% 90% 89% 59%
With pp67 mRNA b) -- - -
cut-off Antigenemia pp65 91% - 80% 77%
Before
CMV Monitor 87% - 57% 78%
treatment
pp67 mRNA b) -- - -
a) No determinations were available before beginning of treatment since this variable requires a disease event b) No cut-off va lue could be used due 
to the method's qualitative natureBMC Infectious Diseases (2001) 1:2 http://www.biomedcentral.com/1471-2334/1/2
(patients A and C; table 3), and exclude 1 patient that de-
veloped disease (patient J, that showed negative deter-
minations by all methods used; table 3). Similarly,
although pp67 mRNA determinations correctly identi-
fied 2 patients that did not develop disease, this was not
the case for the remaining 3 patients.
We then compared statistically the performance of the 3
methods using all determinations before onset of disease
(table 4). Since the desired outcome is to be able to iden-
tify patients at risk of developing CMV related disease,
the most relevant statistical determinations are the pos-
itive predictive value and the negative predictive value.
Interestingly, these determinations were far better for
the pp67 mRNA methods when only the determinations
before beginning of treatment were considered (table 4).
Furthermore, for the same determinations, and with the
exception of pp65 antigenemia positive predictive value,
the refinement introduced into pp65 antigenemia and
CMV monitor by the inclusion of cut-off values did not
significantly improve the respective negative and posi-
tive predictive values relative to raw pp67 mRNA deter-
minations (table 4). Also the specificity of the pp67
mRNA assay was found to be better than the observed
with the antigenemia and CMV monitor raw data before
beginning of ganciclovir treatment.
Finally, when taking in consideration all determinations,
the 3 methods seemed to behave similarly (table 4),
again, with slightly better raw data performance ob-
served for the pp67 mRNA assay.
Discussion
All 10 liver transplant recipients developed CMV infec-
tion after transplantation. The onset of infection oc-
curred between the 3rd and the 4th week post-
transplant, which is in accordance with the literature [1].
Detection of infection was found to be of little clinical sig-
nificance, since only 5/10 patients developed CMV dis-
ease. It must however be stressed that the present
sample was specifically chosen to include a similar
number of patients with and without disease (see mate-
rials and methods section), and does not reflect the over-
all CMV disease incidence in the Liver Transplant Unit.
In fact, the readily available data on 136 of the total 190
patients showed that despite 105 patients (77,2%) show-
ing positive antigenemia results, only 13 patients
(10.46%) developed CMV disease (3 of these were CMV
seronegative at transplantation).
Antigenemia and CMV monitor were equally sensitive in
the detection of CMV infection. However, the results ob-
tained by pp67 mRNA assay were clinically more signifi-
cant, as 2 patients that never showed infection by this
method, did not develop disease. The onset of infection
was detected earlier by antigenemia than by the molecu-
lar biology assays. However, this difference was only
seen in patients that did not develop CMV disease. This
curious observation may reflect the different protein/
mRNA targeted, as well as the different clinical material
used by each assay. Antigenemia targets the detection of
an immediate early antigen within infected cells. It is
thus capable of detecting CMV at a very early stage of in-
fection. The pp67 mRNA detected by the NASBA assay is
a delayed early gene that should be detected at a slightly
latter phase of infection. Finally, the CMV monitor assay
is targeting the detection of the polymerase gene on plas-
ma, and should therefore be positive only if viral parti-
cles are circulating in the blood stream. Therefore, this
method should be expected to be the last to detect CMV
infection. Adding to these differences, also the effect of
immune system mediated viral clearance can be expect-
ed to differentially influence the results on the 3 different
assays used. The early antigens/mRNA species could be
detected even in the cases where the immune surveil-
lance will suffice to prevent CMV disease, whereas detec-
tion of circulating viral particles could be expected to be
clinically more significant in this regard. Thus, the obser-
vation that antigenemia CMV detection is only detected
earlier among patients that do not develop disease may
also be the result of a faster evolving infection kinetics
among the patients whose immune system is unable to
control the infection.
Not surprisingly, viral load at the onset of infection was
found to be higher among patients that developed dis-
ease than among patients that remained assymptomatic.
Furthermore it was curious to observe that the onset of
infection was earlier in patients that developed disease
than in the patients without disease, suggesting that the
earlier the infection, the higher the clinical risk. In fact,
both molecular biology methods never detected the on-
set of infection before day 32 in patients without disease,
whereas in patients with disease the detection of the on-
set of infection was until day 35. These two observations
are in agreement with previous reports by others
[19,20,21,22] and support the possible use of kinetic
trends as well as viral load data in the identification of
patients at risk of developing CMV related disease. This
could be an important contribution, since it was difficult
to relate viremia results alone to the clinical disease sta-
tus. Neither pp67 mRNA assay, nor CMV monitor or an-
tigenemia pp65 determinations produced results readily
distinguishable between patients with and without dis-
ease. The only possible discrimination by viral load was
obtained by defining a cut-off value for antigenemia of 8
positive cells per 50.000, which is in agreement with the
4-6 cells/slide described in a previous independent study
[13]. When the data is treated this way, patients with dis-
ease were generally distinguishable from patients with-BMC Infectious Diseases (2001) 1:2 http://www.biomedcentral.com/1471-2334/1/2
out disease. Similarly, the best discriminative value for
the CMV monitor assay (2000 copies/ml) is in agree-
ment with the 2000-5000 copies/ml previously de-
scribed by others [13]. CMV pp67 mRNA assay was the
only method whose raw data showed negative values in
some (but not all) of the patients without clinical disease,
presenting one false negative (a false negative identified
as such by all 3 methods), and 3 false positives. However,
it must be reinforced that the false positive values ob-
served both for CMV monitor and CMV pp67 mRNA as-
say could be correctly interpreted if viremia kinetics were
taken into consideration, since in all these cases positive
values occurred after the 30th day post-transplant (see
fig 1).
Finally, when all data observed until beginning of ganci-
clovir therapy was considered, pp67 mRNA assay was
also the method that showed the best positive and nega-
tive predictive values. Furthermore, contrary to CMV
monitor determinations, pp67 mRNA results were also
found to be of use for the follow-up of the response to an-
tiviral therapy, further increasing its potential usefulness
for the assessment of patients after liver transplantation.
Conclusion
Molecular biology methods alone did not seem to dis-
criminate patients at risk of developing CMV disease bet-
ter than antigenemia. Thus, although the small number
of patients studied does not allow us to reach definite
conclusions, if only one test is to be used, antigenemia
seems to be the best choice. It appears however that mo-
lecular biology methods have a better performance in
discriminating the kinetics of the onset of infection,
which seemed to correlate well to the risk of developing
CMV disease. Furthermore, despite its qualitative na-
ture, CMV pp67 mRNA assay was, in hour hands, with-
out the need to use arbitrarily defined cut-off values, the
method with the best negative and positive predictive
values for the development of CMV disease. Thus, our re-
sults support the need for larger studies testing the pos-
sible advantage of concomitantly use antigenemia and
pp67 mRNA assays to the prediction of CMV disease in
liver transplant recipients.
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